Oncology | nashvillepost.com

After deal, US Radiosurgery stays put

Alliance Oncology’s acquisition of US Radiosurgery will expand the scope of operations handled by the Nashville company.

Alliance announced its $54 million purchase of US Radiosurgery on Tuesday. Under the deal, Alliance will shift the management of its steretotactic radiosurgery centers to US Radiosurgery, which will continue its operations in Nashville and retain its brand as a division of Alliance. George Stevens, CEO of US Radiosurgery, said the deal “almost doubles” the number of centers it’s supporting and gives the company a strong development base.

“At this time we have our largest pipeline in the history of the company,” Stevens said.

Apr 15, 2011 12:42 PM

US Radiosurgery acquired for $54M

Alliance HealthCare division snaps up Nashville company

Apr 12, 2011 10:21 AM

Texas partnership for U.S. Radiosurgery

U.S. Radiosurgery, the Nashville-based company chaired by Rock Morphis and run by George Stevens, has signed its 10th partnership, a deal to manage the CyberKnife cancer treatment program at a facility in Austin.

Feb 22, 2011 9:40 AM

Vanderbilt-Ingram Cancer Center names CMO

Oncologist relocating from large Cincinnati doctor group

Feb 3, 2011 1:36 PM

SCRI joins research consortium

The Sarah Cannon Research Institute has joined the network of sites that make up the Multiple Myeloma Research Consortium. Along with Nashville-based SCRI, which conducts trials through a network of some 450 doctors in 27 states, organizations in Dallas and suburban D.C. also have joined the consortium, which now comprises 16 groups.

Dec 23, 2010 9:51 AM

DiaTech Oncology files for patent

Brentwood-based lab company DiaTech Oncology said today it's filed for a drug discovery patent for its Microculture Kinetic (MiCK) assay, a drug validation test that measures the timing and amount of cell death in tumor cells caused by chemotherapy or anticancer drugs:

Pharmaceutical companies can then concentrate development resources on drugs that are most active against tumor cells, and can also identify which patients might respond best to the experimental chemotherapy agents in clinical trials. Because of this unique capability the MiCK assay can be a valuable tool in the field of Drug Discovery by reducing the costs associated with validation studies and the time required to obtain FDA approval for marketing.

For more on DiaTech, click here.

Sep 7, 2010 11:36 AM

VICC's No. 2 moving to Texas

David Johnson, deputy director of the Vanderbilt-Ingram Cancer Center, is leaving the university after almost three decades for the University of Texas Southwestern, where he will be chairman of medicine and hold an endowed chair. Carlos Arteaga will take over the leadership of VICC's division of hematology and oncology until a permanent successor is hired.

Apr 29, 2010 3:03 PM

TMA announces president, pres-elect

The Tennessee Medical Association today announced Dr. B.W. Ruffner will be installed as the physician organizaiton's 156th president at its annual meeting April 10. Ruffner, a medical oncologist and internal medicine speciliast from Chattanooga, has been on the medical staff at Erlanger Medical Center fro 33 years. In addition, TMA announced Dr. Michael Minch as its president-elect for 2010. The Nashville surgeon has served as chairman and vice-chairman of the TMA's Board of Trustees and is the co-founder and former CEO of Diabetes Care Club, which is now part of Simplex Healthcare. See also: Today's print story on health care reform's impact on Tennessee physicians.

Apr 5, 2010 12:20 PM

'The added complexity is worth the effort'

The head of Tennessee Oncology talks about growing the practice beyond its traditional roots [From our print edition featured in Monday's City Paper]

Mar 21, 2010 3:15 PM